Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.

@article{Roboz2008ArsenicTA,
  title={Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.},
  author={Gail J. Roboz and Ellen Kelly Ritchie and Tania J Curcio and Juliette Provenzano and Rebecca Carlin and Michael S Samuel and Beth Wittenberg and Madhu Mazumdar and Paul J. Christos and Susan Wndy Mathew and Sandra Allen-Bard and Eric J. Feldman},
  journal={Cancer},
  year={2008},
  volume={113 9},
  pages={2504-11}
}
BACKGROUND Acute myeloid leukemia (AML) carries a dismal prognosis in older patients. In this study, the authors evaluated the safety and efficacy of arsenic trioxide combined with low-dose cytarabine in untreated patients aged >or=60 years with AML. METHODS In a phase 1/2 design, arsenic trioxide was administered intravenously at a dose of 0.25 mg/kg on Days 1 through 5 and on Days 8 through 12, and low-dose cytarabine was given subcutaneously twice daily on Days 1 through 14 in escalating… CONTINUE READING